| Molly Elizabeth Hester-conway, FNP | |
|
1031 Northridge Rd, Baldwyn, MS 38824-1173 | |
| (662) 365-9305 | |
| (662) 365-9304 |
| Full Name | Molly Elizabeth Hester-conway |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 19 Years |
| Location | 1031 Northridge Rd, Baldwyn, Mississippi |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1851331805 | NPI | - | NPPES |
| 05109339 | Medicaid | MS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163W00000X | Registered Nurse | R865549 (Mississippi) | Secondary |
| 363LF0000X | Nurse Practitioner - Family | R865549 (Mississippi) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| North Mississippi Medical Center Inc | 9931010600 | 295 |
News Archive
Molecular Health announced today it has been granted a patent in Europe entitled "Tissue Protective Erythropoietin Receptor". This latest patent supports Molecular Health's discovery that EPHB4 is a novel receptor for Erythropoietin (EPO), where EPHB4 binds to EPO and promotes tumor growth.
Arisaph Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on discovery and development of novel therapies for cardiometabolic diseases and cancer, announced today that it has been awarded a phase II Small Business Technology Transfer (STTR) grant and a supplemental phase I grant, both from the National Cancer Institute of the National Institutes of Health.
The passage of sweeping healthcare legislation and the recent election of the 112th Congress make these exciting but uncertain times for American healthcare. The National Quality Forum's annual conference, "Achieving Health of Individuals and Populations Within Their Communities," will focus on population health and bring together policymakers and key public- and private-sector stakeholders, each representing their own perspectives for improving health and healthcare throughout the country.
Researchers have discovered the genetic processes that cause specific types of bowel cancer. Using this knowledge, they identified cancer drugs that target these genes. Their findings offer the opportunity to develop personalised treatment based on a person's genetic profile.
› Verified 7 days ago
| Entity Name | North Mississippi Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972608347 PECOS PAC ID: 9931010600 Enrollment ID: O20040413000541 |
News Archive
Molecular Health announced today it has been granted a patent in Europe entitled "Tissue Protective Erythropoietin Receptor". This latest patent supports Molecular Health's discovery that EPHB4 is a novel receptor for Erythropoietin (EPO), where EPHB4 binds to EPO and promotes tumor growth.
Arisaph Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on discovery and development of novel therapies for cardiometabolic diseases and cancer, announced today that it has been awarded a phase II Small Business Technology Transfer (STTR) grant and a supplemental phase I grant, both from the National Cancer Institute of the National Institutes of Health.
The passage of sweeping healthcare legislation and the recent election of the 112th Congress make these exciting but uncertain times for American healthcare. The National Quality Forum's annual conference, "Achieving Health of Individuals and Populations Within Their Communities," will focus on population health and bring together policymakers and key public- and private-sector stakeholders, each representing their own perspectives for improving health and healthcare throughout the country.
Researchers have discovered the genetic processes that cause specific types of bowel cancer. Using this knowledge, they identified cancer drugs that target these genes. Their findings offer the opportunity to develop personalised treatment based on a person's genetic profile.
› Verified 7 days ago
| Entity Name | Pain Management Center Of North |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811928724 PECOS PAC ID: 9638147408 Enrollment ID: O20040920000649 |
News Archive
Molecular Health announced today it has been granted a patent in Europe entitled "Tissue Protective Erythropoietin Receptor". This latest patent supports Molecular Health's discovery that EPHB4 is a novel receptor for Erythropoietin (EPO), where EPHB4 binds to EPO and promotes tumor growth.
Arisaph Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on discovery and development of novel therapies for cardiometabolic diseases and cancer, announced today that it has been awarded a phase II Small Business Technology Transfer (STTR) grant and a supplemental phase I grant, both from the National Cancer Institute of the National Institutes of Health.
The passage of sweeping healthcare legislation and the recent election of the 112th Congress make these exciting but uncertain times for American healthcare. The National Quality Forum's annual conference, "Achieving Health of Individuals and Populations Within Their Communities," will focus on population health and bring together policymakers and key public- and private-sector stakeholders, each representing their own perspectives for improving health and healthcare throughout the country.
Researchers have discovered the genetic processes that cause specific types of bowel cancer. Using this knowledge, they identified cancer drugs that target these genes. Their findings offer the opportunity to develop personalised treatment based on a person's genetic profile.
› Verified 7 days ago
| Entity Name | Acute Care & Family Clinic Of Mooreville |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619298536 PECOS PAC ID: 2961697578 Enrollment ID: O20101109000853 |
News Archive
Molecular Health announced today it has been granted a patent in Europe entitled "Tissue Protective Erythropoietin Receptor". This latest patent supports Molecular Health's discovery that EPHB4 is a novel receptor for Erythropoietin (EPO), where EPHB4 binds to EPO and promotes tumor growth.
Arisaph Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on discovery and development of novel therapies for cardiometabolic diseases and cancer, announced today that it has been awarded a phase II Small Business Technology Transfer (STTR) grant and a supplemental phase I grant, both from the National Cancer Institute of the National Institutes of Health.
The passage of sweeping healthcare legislation and the recent election of the 112th Congress make these exciting but uncertain times for American healthcare. The National Quality Forum's annual conference, "Achieving Health of Individuals and Populations Within Their Communities," will focus on population health and bring together policymakers and key public- and private-sector stakeholders, each representing their own perspectives for improving health and healthcare throughout the country.
Researchers have discovered the genetic processes that cause specific types of bowel cancer. Using this knowledge, they identified cancer drugs that target these genes. Their findings offer the opportunity to develop personalised treatment based on a person's genetic profile.
› Verified 7 days ago
| Entity Name | Willow Pain And Wellness Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093188096 PECOS PAC ID: 7113201849 Enrollment ID: O20170224001178 |
News Archive
Molecular Health announced today it has been granted a patent in Europe entitled "Tissue Protective Erythropoietin Receptor". This latest patent supports Molecular Health's discovery that EPHB4 is a novel receptor for Erythropoietin (EPO), where EPHB4 binds to EPO and promotes tumor growth.
Arisaph Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on discovery and development of novel therapies for cardiometabolic diseases and cancer, announced today that it has been awarded a phase II Small Business Technology Transfer (STTR) grant and a supplemental phase I grant, both from the National Cancer Institute of the National Institutes of Health.
The passage of sweeping healthcare legislation and the recent election of the 112th Congress make these exciting but uncertain times for American healthcare. The National Quality Forum's annual conference, "Achieving Health of Individuals and Populations Within Their Communities," will focus on population health and bring together policymakers and key public- and private-sector stakeholders, each representing their own perspectives for improving health and healthcare throughout the country.
Researchers have discovered the genetic processes that cause specific types of bowel cancer. Using this knowledge, they identified cancer drugs that target these genes. Their findings offer the opportunity to develop personalised treatment based on a person's genetic profile.
› Verified 7 days ago
| Entity Name | Panola Physician Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528528874 PECOS PAC ID: 2668715624 Enrollment ID: O20190515002618 |
News Archive
Molecular Health announced today it has been granted a patent in Europe entitled "Tissue Protective Erythropoietin Receptor". This latest patent supports Molecular Health's discovery that EPHB4 is a novel receptor for Erythropoietin (EPO), where EPHB4 binds to EPO and promotes tumor growth.
Arisaph Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on discovery and development of novel therapies for cardiometabolic diseases and cancer, announced today that it has been awarded a phase II Small Business Technology Transfer (STTR) grant and a supplemental phase I grant, both from the National Cancer Institute of the National Institutes of Health.
The passage of sweeping healthcare legislation and the recent election of the 112th Congress make these exciting but uncertain times for American healthcare. The National Quality Forum's annual conference, "Achieving Health of Individuals and Populations Within Their Communities," will focus on population health and bring together policymakers and key public- and private-sector stakeholders, each representing their own perspectives for improving health and healthcare throughout the country.
Researchers have discovered the genetic processes that cause specific types of bowel cancer. Using this knowledge, they identified cancer drugs that target these genes. Their findings offer the opportunity to develop personalised treatment based on a person's genetic profile.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Molly Elizabeth Hester-conway, FNP Po Box 429, Verona, MS 38879-0429 Ph: (662) 566-5593 | Molly Elizabeth Hester-conway, FNP 1031 Northridge Rd, Baldwyn, MS 38824-1173 Ph: (662) 365-9305 |
News Archive
Molecular Health announced today it has been granted a patent in Europe entitled "Tissue Protective Erythropoietin Receptor". This latest patent supports Molecular Health's discovery that EPHB4 is a novel receptor for Erythropoietin (EPO), where EPHB4 binds to EPO and promotes tumor growth.
Arisaph Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on discovery and development of novel therapies for cardiometabolic diseases and cancer, announced today that it has been awarded a phase II Small Business Technology Transfer (STTR) grant and a supplemental phase I grant, both from the National Cancer Institute of the National Institutes of Health.
The passage of sweeping healthcare legislation and the recent election of the 112th Congress make these exciting but uncertain times for American healthcare. The National Quality Forum's annual conference, "Achieving Health of Individuals and Populations Within Their Communities," will focus on population health and bring together policymakers and key public- and private-sector stakeholders, each representing their own perspectives for improving health and healthcare throughout the country.
Researchers have discovered the genetic processes that cause specific types of bowel cancer. Using this knowledge, they identified cancer drugs that target these genes. Their findings offer the opportunity to develop personalised treatment based on a person's genetic profile.
› Verified 7 days ago
Richard Comer, FNP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 529 S Fourth St, Baldwyn, MS 38824 Phone: 662-620-1496 Fax: 662-365-2255 | |
Maggie Martin Smith, PMHNP-BC Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 825 Road 1275, Baldwyn, MS 38824 Phone: 662-397-1106 | |
Miranda Lou Ford, NP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 121 S 2nd St, Baldwyn, MS 38824 Phone: 662-365-2725 | |
Mrs. Anita Joy Turner, FNP Nurse Practitioner Medicare: May Accept Medicare Assignments Practice Location: 1031 Northridge Rd, Baldwyn, MS 38824 Phone: 662-365-9305 Fax: 662-365-9304 | |
Mrs. Heather Hancock, FNP Nurse Practitioner Medicare: May Accept Medicare Assignments Practice Location: 1031 Northridge Rd, Baldwyn, MS 38824 Phone: 662-365-9305 Fax: 662-365-9304 | |
Larry Richard Arnold, FNP-C Nurse Practitioner Medicare: May Accept Medicare Assignments Practice Location: 1031 Northridge Rd, Baldwyn, MS 38824 Phone: 662-365-9305 | |
Louise Cristo, NP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 739 S Fourth St, Baldwyn, MS 38824 Phone: 662-401-1472 |